Trial
NCT05126329
Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
—
Condition
Hepatic Function Abnormal
Intervention
amcenestrant
Why stopped
Sponsor decision to prematurely stop the study, not linked to any safety concern
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-22